Agios Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2026, with the SEC on November 5, 2026, disclosing product revenue growth, continued operating losses, and updated balance sheet figures.

Key Highlights

  • Q3 2026 product revenue, net: $55,385 thousand, compared to $12,880 thousand in Q3 2025, according to the filing.
  • Q3 2026 net loss: $(65,045) thousand, or $(1.09) per basic and diluted share, versus a net loss of $(103,433) thousand, or $(1.78) per share, in Q3 2025.
  • Nine-month net loss: $(264,859) thousand, or $(4.46) per share, for the nine months ended September 30, 2026, compared to $(304,742) thousand, or $(5.27) per share, for the same period in 2025.
  • Total assets as of September 30, 2026: $1,064,040 thousand, down from $1,297,225 thousand at December 31, 2025.
  • Cash and cash equivalents: $128,549 thousand at September 30, 2026, up from $89,130 thousand at December 31, 2025.
  • Accumulated deficit: $(826,564) thousand at September 30, 2026, compared to $(561,705) thousand at December 31, 2025.
  • Shares outstanding: 59,780,890 common shares as of September 30, 2026, with 59,809,651 shares outstanding as of October 30, 2026.

Agios Reports Revenue Growth and Narrower Quarterly Loss in Q3 2026

According to the Form 10-Q filed with the SEC, Agios Pharmaceuticals (NASDAQ:AGIO) reported total product revenue, net of $55,385 thousand for the three months ended September 30, 2026, a substantial increase from $12,880 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, net product revenue totaled $120,876 thousand, up from $34,061 thousand in the first nine months of 2025. The filing notes that total revenue in each period consisted entirely of product revenue, net.

The company reported total operating expenses of $132,545 thousand in Q3 2026, compared to $129,749 thousand in Q3 2025. Research and development expenses were $73,487 thousand in Q3 2026 versus $86,796 thousand in Q3 2025, while selling, general and administrative expenses rose to $56,533 thousand from $41,274 thousand in the prior-year quarter. The filing also disclosed royalty income from gain on sale of oncology business of $2,969 thousand for Q3 2026, with no comparable amount in Q3 2025. Interest income, net, was $8,880 thousand in Q3 2026 versus $13,369 thousand in Q3 2025.

On the balance sheet, the filing reported total stockholders' equity of $979,336 thousand at September 30, 2026, compared to $1,193,114 thousand at December 31, 2025. Combined current and non-current marketable securities totaled $778,469 thousand at September 30, 2026, down from $1,075,308 thousand at December 31, 2025. Total liabilities stood at $84,704 thousand, compared to $104,111 thousand at year-end 2025. Treasury stock remained unchanged at 16,216,411 shares, carried at a cost of $(802,486) thousand.

What Was Disclosed

Agios Pharmaceuticals filed its Q3 2026 Form 10-Q covering the three and nine months ended September 30, 2026, disclosing product revenue growth, continued net losses, reduced total assets, and updated stockholders' equity and cash positions relative to December 31, 2025.